Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer

[1]  E. Diamandis,et al.  Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[3]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[4]  E. Diamandis,et al.  Prostate-specific antigen in female serum, a potential new marker of androgen excess. , 1997, The Journal of clinical endocrinology and metabolism.

[5]  E. Diamandis,et al.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. , 1997, British Journal of Cancer.

[6]  E. Diamandis.  Prostate specific antigen--new applications in breast and other cancers. , 1996, Anticancer research.

[7]  E. Diamandis,et al.  Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. , 1996, British Journal of Cancer.

[8]  P. Lavagnini,et al.  Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. , 1996, British Journal of Cancer.

[9]  T. Lennard,et al.  Prostate‐specific antigen in breast cyst fluid: Possible role of prostate‐specific antigen in hormone‐dependent breast cancer , 1996 .

[10]  E. Diamandis,et al.  Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. , 1996, Clinical chemistry.

[11]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  E. Diamandis,et al.  Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. , 1995, British Journal of Cancer.

[13]  D. Katsaros,et al.  Prostate-specific antigen in serum of women with breast cancer. , 1995, British Journal of Cancer.

[14]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[15]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[16]  C. Croce,et al.  Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. , 1995, Cancer research.

[17]  E. Diamandis,et al.  Prostate‐Specific antigen expression by various tumors , 1995, Journal of clinical laboratory analysis.

[18]  S. Hilsenbeck,et al.  Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. , 1994, Journal of the National Cancer Institute.

[19]  R. Rosato,et al.  Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. , 1994, Endocrinology.

[20]  J. Foekens,et al.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.

[21]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[22]  T. Laatikainen,et al.  Plasma insulin‐like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen , 1994, Cancer.

[23]  N. Ling,et al.  Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. , 1994, Cancer research.

[24]  M. Binoux,et al.  In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. , 1994, The Journal of clinical investigation.

[25]  E. Diamandis,et al.  Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. , 1994, Clinical biochemistry.

[26]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[27]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[28]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[29]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[30]  P. Lønning,et al.  Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. , 1992, Cancer research.

[31]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Campbell,et al.  Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. , 1992, Endocrinology.

[33]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[34]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[35]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[36]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[37]  W. Sly,et al.  Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.

[38]  C. Osborne,et al.  Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.

[39]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[40]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[41]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[42]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[43]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[44]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[45]  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .